In the phase I trial, 69.6% of CML patients in chronic‐phase (CML‐CP) were still under treatment after a median exposure of approximately 4 years, and 61.6% reached or maintained major molecular response (MMR) (BCR::ABL1 transcript ≤ 0.1%, also referred as MR3), confirming asciminib long‐term tolerability and efficacy [16]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.